DEFA14A: OraSure Defends Board Amid Altai Capital Director Challenge

OraSure Technologies confirmed Altai Capital's intent to nominate two director candidates for the 2026 Annual Meeting, stating its commitment to shareholder value and board independence.

Summary

• OraSure Technologies confirmed Altai Capital's intent to nominate two director candidates, including Rishi Bajaj, for the 2026 Annual Meeting of Stockholders.
• The Board previously evaluated Mr. Bajaj for service but determined not to appoint him.
• OraSure emphasizes its strong, independent, and engaged Board, noting significant refreshment with seven directors departing and three new independent directors added in the past three years.
• Steven K. Boyd, an accomplished healthcare investor, joined the Board in October 2025, and John P. Kenny was appointed Chair in October 2025.
• The company is executing a strategy to decentralize diagnostics, focusing on innovation, consolidating operations, insourcing manufacturing, and exiting unprofitable business lines.
• Near-term milestones include anticipated FDA submissions for Sherlock rapid molecular self-test for CT/NG and Colli-Pee at-home urine collection device, and the launch of HEMAcollect PROTEIN blood collection tube for research use.
• OraSure maintains a healthy cash position of $216 million as of September 30, 2025, with no debt, and is right-sizing its cost structure for sustainable profitability.
• The Board initiated a new $40 million share repurchase program earlier this year, and the CEO and CFO adopted Rule 10b5-1 trading plans for stock purchases.
• The Nominating and Corporate Governance Committee will review formal nominations from Altai and present Board recommendations to shareholders.

Sentiment

Score: 6

Explanation: The company is actively defending its board and strategy against an activist investor, which introduces uncertainty. However, it highlights strong cash, a share repurchase program, and a clear strategic roadmap with upcoming product milestones, indicating confidence in its direction despite the challenge.

Positives

• Strong cash position of $216 million as of September 30, 2025, with no debt.
• Execution of a new $40 million share repurchase program.
• CEO and CFO adopted Rule 10b5-1 trading plans for common stock purchases, indicating management confidence.
• Significant Board refreshment with three new, highly qualified independent directors added in the past three years, including Steven K. Boyd in October 2025.
• Appointment of John P. Kenny as Board Chair in October 2025.
• Clear strategic focus on decentralizing diagnostics, innovation roadmap, and high-growth opportunities.
• Anticipated FDA submissions for Sherlock rapid molecular self-test for CT/NG and Colli-Pee at-home urine collection device.
• Launch of HEMAcollect PROTEIN blood collection tube for research use.
• Consolidating operations, insourcing manufacturing, and exiting unprofitable business lines to improve margins and achieve sustainable profitability.

Negatives

• Altai Capital's intent to nominate two director candidates suggests dissatisfaction with current board composition or company performance.
• The Board's prior decision not to appoint Rishi Bajaj, Altai's founder, to serve as a director.
• Altai Capital has not accepted invitations for further engagement with OraSure directors.

Risks

• Ability to satisfy customer demand.
• Ability to reduce spending rate, capitalize on manufacturing efficiencies, and drive profitable growth.
• Ability to market and sell products and services.
• Impact of significant customer concentration in the genomics business.
• Failure of distributors or other customers to meet purchase forecasts or requirements.
• Ability to manufacture products in accordance with specifications and quality requirements.
• Ability to obtain, and timing/cost of obtaining, necessary regulatory approvals for new products or indications.
• Ability to comply with applicable regulatory requirements and resolve findings from regulators.
• Changes in relationships with strategic partners and reliance on them.
• Impact of replacing distributors.
• Inventory levels at distributors and customers.
• Ability to achieve financial and strategic objectives, increase revenues, expand international sales, and reduce costs.
• Impact of competitors, competing products, and technology changes.
• Reduction or deferral of public funding available to customers.
• Competition from new or better technology or lower cost products.
• Ability to develop, commercialize, and market new products.
• Market acceptance of products and services.
• Ability to achieve anticipated benefits from the BioMedomics transaction.
• Changes in market acceptance of products based on performance or testing guidelines.
• Ability to fund research and development and other operations.
• Ability to obtain and maintain new or existing product distribution channels.
• Reliance on sole supply sources for critical products and components.
• Availability of related products produced by third parties or products required for use of OraSure's products.
• Impact of contracting with the U.S. government.
• Impact of negative economic conditions.
• Ability to achieve and maintain sustained profitability and increase gross margins.
• Ability to utilize net operating loss carry forwards or other deferred tax assets.
• Volatility of stock price.
• Uncertainty relating to patent protection and potential patent infringement claims.
• Uncertainty and costs of litigation relating to intellectual property.
• Availability of licenses to patents or other technology.
• Ability to enter into international manufacturing agreements and obstacles to international marketing/manufacturing.
• Ability to sell products internationally, including impact of changes in international funding sources and testing algorithms.
• Adverse movements in foreign currency exchange rates.
• Loss or impairment of sources of capital.
• Ability to attract and retain qualified personnel.
• Exposure to product liability and other types of litigation.
• Changes in international, federal, or state laws and regulations.
• Customer consolidations and inventory practices.
• Equipment failures and ability to obtain needed raw materials and components.
• Cybersecurity incidents and other disruptions involving computer systems.
• Impact of terrorist attacks, civil unrest, hostilities, and war.
• General political, business, and economic conditions, including interest rates, inflationary pressures, capital market disruptions, changes in governmental agencies, international tariffs, trade protection measures, economic sanctions, and economic slowdowns or recessions.

Future Outlook

OraSure anticipates near-term milestones including FDA submissions for its Sherlock rapid molecular self-test for CT/NG and Colli-Pee at-home urine collection device, as well as the launch of HEMAcollect PROTEIN blood collection tube for research use. The company is focused on driving profitable growth, improving margins, and achieving sustainable profitability through strategic execution, including consolidating operations, insourcing manufacturing, and exiting unprofitable business lines.

Management Comments

• "The OraSure Board and management team are committed to moving the Company forward with a clear focus on shareholder value creation."
• "We maintain open and constructive dialogue with our shareholders, and members of OraSures Board have engaged extensively with Altai Capital in recent months, including evaluating Mr. Bajaj for potential service on the Board."
• "Our Board ultimately determined not to appoint Mr. Bajaj to serve as a director at OraSure."
• "OraSure maintains a strong, independent, and engaged Board."
• "We continually assess our Board composition, and as a result our Board has undergone significant refreshment, bringing in industry perspectives and executive-level experience to provide oversight as management drives growth and value creation."
• "OraSure is executing on a strategy to decentralize diagnostics by connecting people to healthcare wherever they are, and we are taking decisive steps to improve our performance."
• "Reflecting our confidence in OraSure and its earnings potential as well as our ability to deliver value for all shareholders, earlier this year our Board began executing on a new $40 million share repurchase program."
• "We will continue to take actions that we believe are in the best interests of shareholders."

Industry Context

The announcement highlights OraSure's strategy to decentralize diagnostics, aligning with a broader industry trend towards point-of-need and at-home testing solutions. This strategy aims to improve access, quality, and value of healthcare by connecting people to diagnostics wherever they are, a key driver in the evolving healthcare landscape, particularly in the context of increasing demand for convenient and accessible health services.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential impact from the proxy contest, but the company's actions (share repurchase, strategic plan) aim to create value. The Board's recommendations for director nominations will directly affect their voting decisions.
• Employees: Strategic initiatives like consolidating operations, insourcing manufacturing, and exiting unprofitable business lines could lead to operational changes, potentially impacting employees in those areas.
• Customers: Innovation roadmap and anticipated FDA submissions for new diagnostic products could offer enhanced solutions.
• Suppliers/Partners: Changes in manufacturing strategy (insourcing) and exiting business lines could affect existing supplier relationships. Reliance on sole supply sources is also noted as a risk.
• Creditors: The healthy cash position and no debt indicate a strong financial standing, which is positive for creditors.

Next Steps

• OraSure's Nominating and Corporate Governance Committee and Board will review formal director nominations from Altai Capital.
• The Board will present its recommendations to shareholders in due course.
• OraSure intends to file a proxy statement and a white proxy card with the SEC for the 2026 Annual Meeting.

Key Dates

Recommendation

The company is facing a proxy contest from an activist investor, which introduces uncertainty and potential for governance changes. While OraSure highlights a strong cash position, a share repurchase program, and a clear strategic roadmap with upcoming product milestones, the challenge from Altai Capital suggests underlying concerns about performance or strategy. An investor should hold to observe the outcome of the proxy contest and the execution of the stated strategic initiatives before making further investment decisions. The current situation presents both potential for positive change if Altai's proposals are beneficial or if OraSure's defense proves effective, but also risks associated with a contested board.

Keywords

OraSure Technologies, OSUR, Altai Capital, proxy contest, director nomination, corporate governance, shareholder value, diagnostics, sample management, FDA submission, Sherlock, Colli-Pee, HEMAcollect, share repurchase, Rule 10b5-1, healthcare, biotechnology